Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 15/20 | 0.57 |
| ▸ | CHUK | O15111 | 12/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | BTK | Q06187 | 2/20 | 0.57 |
| ▸ | ITK | Q08881 | 2/20 | 0.57 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.57 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658035 | 0.99 | IKBKB (0.56) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5657287 | 0.99 | IKBKB (0.56) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5658512 | 0.98 | IKBKB (0.57) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5657958 | 0.89 | IKBKB (0.55) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5658197 | 0.88 | IKBKB (0.54) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5659073 | 0.88 | IKBKB (0.54) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5659208 | 0.87 | IKBKB (0.67) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5659403 | 0.86 | IKBKB (0.62) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5658209 | 0.86 | IKBKB (0.55) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5655347 | 0.85 | IKBKB (0.57) | IKBKBCHUKCDK2BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | claimed |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | PITTS WILLIAM J | 2006-09-28 | — | — | US | claimed |
| US-20050192339-A1 | Compounds | BIOVITRUM AB (SE) | 2005-09-01 | — | — | US | claimed |
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-12 | — | — | US | claimed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | PITTS WILLIAM J | 2006-09-28 | — | — | US | disclosed |
| US-20050192339-A1 | Compounds | BIOVITRUM AB (SE) | 2005-09-01 | — | — | US | disclosed |
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | IKBKB 243/4885CHUK 197/4885CDK2 350/4885 |
| US-20050192339-A1 | Compounds | MCHR1, HCRTR1, NPY1R | IKBKB 3804/4885CHUK 3023/4885CDK2 2019/4885 |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | IKBKB 151/4885CHUK 272/4885CDK2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.